India’s opportunity to build preventive healthcare economy
The country’s strength lies not just in technology availability but in adoption behaviour
The country’s strength lies not just in technology availability but in adoption behaviour
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Subscribe To Our Newsletter & Stay Updated